FTSE 100

Key insight

The FTSE 100 is trading at all-time-high territory above 10,880, supported by BoE easing and a strong earnings season, but a rotation out of energy (Shell/BP -2%) and pharma (AstraZeneca -6%) on US-Iran deal speculation poses a near-term sector drag that could stall the breakout.

The FTSE 100 is consolidating above the key 10,800 round-number support after a strong 3.5–4.5% July rally, with BoE rate-cut expectations and earnings beats providing a fundamental tailwind toward the 11,000 psychological resistance.

Main risk

AstraZeneca/BMS Merger Speculation & Energy Sector Selloff

AstraZeneca (-6%) and Shell/BP (-2%) together account for a significant FTSE 100 weighting; sustained selling in both sectors simultaneously could drag the index back below the 10,800 support level.